Seed Round

Acurion Raises $4.3M Seed

Acurion raises $4.3M seed round led by TK & Partners at a $4M valuation to advance its AI-driven precision oncology platform and clinical partnerships.

by Ben Murray

Updated June 02, 2026

Acurion Raises $4.3M Seed at $4M Valuation

Acurion, a San Diego, California-based precision oncology technology company developing AI-driven approaches to cancer biomarker detection, has completed an oversubscribed seed round, raising $4.3 million. This marks its initial significant funding to advance its mission in precision medicine.

Investors

The seed round was led by TK & Partners.

Acurion Use of Funds

The newly secured capital will be utilized to advance Acurion's clinical partnerships, supporting its efforts to translate AI innovations into clinically validated healthcare solutions.

About Acurion

Co-Founder and Board Member Magda Marquet, Ph.D., is involved with Acurion. The company's mission is to expand access to precision oncology by improving biomarker detection and treatment selection across multiple advanced cancer types. Acurion develops AI-powered image analysis tools for biomarker detection, uncovering clinically actionable insights from conventional pathology images. Its OncoGaze™ platform applies advanced machine learning to routinely collected pathology slides to identify clinically actionable biomarkers, aiming to accelerate access to precision oncology insights without requiring additional testing infrastructure.